Treatment for ANCA-Associated Vasculitis with RPGN
For ANCA-associated vasculitis presenting with rapidly progressive glomerulonephritis, initiate combination therapy with glucocorticoids plus either rituximab or cyclophosphamide immediately, with rituximab preferred for relapsing disease. 1
Induction Therapy Regimen
First-Line Immunosuppression
The cornerstone of treatment combines:
- Glucocorticoids: Start with oral prednisolone 50-75 mg/day (based on body weight), tapering to 5 mg/day by 4-5 months 1
- Plus either:
- Rituximab (preferred for relapsing disease) OR
- Cyclophosphamide
Both rituximab and cyclophosphamide have equivalent efficacy for new-onset disease, but rituximab demonstrates superiority in relapsing cases 1. The 2024 EULAR guidelines provide the strongest recommendation (Level 1a evidence, Grade A) for this combination approach 1.
Glucocorticoid-Sparing Strategy
Avacopan (C5a receptor inhibitor) may be added to rituximab or cyclophosphamide to substantially reduce glucocorticoid exposure 1. This is particularly valuable for patients with:
- Severe kidney injury requiring rapid functional recovery 2
- High risk of glucocorticoid-related complications 3
- Refractory disease 2
Real-world evidence supports avacopan's effectiveness in RPGN, enabling greater kidney function recovery especially in acute kidney injury 2.
Role of Plasma Exchange
Plasma exchange may be considered for severe renal involvement (serum creatinine >300 µmol/L or >500 µmol/L depending on guideline) but is NOT routinely recommended 1, 4.
The evidence here is nuanced:
- The 2024 EULAR guidelines downgraded plasma exchange to "may be considered" rather than routine use 1
- The 2022 BMJ guideline and KDIGO 2020 similarly recommend against routine use 4
- Consider plasma exchange specifically when:
Critical pitfall: Do NOT delay immunosuppression while arranging plasma exchange—start glucocorticoids and rituximab/cyclophosphamide immediately 1.
Maintenance Therapy
After achieving remission (typically 3-6 months):
- Rituximab is recommended as first-line maintenance therapy 1
- Alternatives include azathioprine or methotrexate 1
- Continue maintenance for 24-48 months for new-onset disease 1
- Consider longer duration (>48 months) for relapsing patients or those with high relapse risk 1
Monitoring and Reassessment
Base treatment decisions on structured clinical assessment rather than ANCA titers or CD19+ B cell counts alone 1. ANCA levels do not reliably predict relapse or guide therapy adjustments.
For refractory disease (failure to respond to induction therapy):
- Perform thorough reassessment to exclude infection, malignancy, or alternative diagnoses 1
- Refer to or manage in conjunction with a specialized vasculitis center 1
- Consider switching between rituximab and cyclophosphamide if one fails 1
Key Clinical Caveats
Biopsy confirmation is strongly recommended before initiating therapy when feasible, as it distinguishes ANCA vasculitis from other causes of RPGN (e.g., MGRS in patients with paraproteinemia) 1, 5. However, do not delay treatment if biopsy cannot be obtained rapidly in life-threatening presentations.
Infection risk is substantial: The case reports demonstrate fatal outcomes from Staphylococcus aureus bacteremia and other infections during immunosuppression 5. Balance aggressive immunosuppression against infection risk, particularly in elderly patients with comorbidities 6, 5.
Delayed diagnosis carries severe consequences: Even with guideline-adherent therapy, delayed recognition can result in dialysis dependency 6, 7. Early nephrology referral and ANCA testing are critical when unexplained acute kidney injury develops with active urinary sediment.